A major scientific breakthrough could transform the way vaccines are stored and distributed, with researchers developing a vaccine formulation that may no longer require constant refrigeration, potentially improving access to life-saving immunisations in remote and low-resource communities.
For decades, vaccines have depended on a strict “cold chain” system, requiring continuous refrigeration from the point of manufacture to the moment they are administered. While essential for preserving vaccine effectiveness, maintaining this temperature-controlled supply chain has remained one of the biggest obstacles to global immunisation, particularly in rural areas, conflict zones and developing countries where electricity and refrigeration facilities are often unreliable.
The World Health Organization (WHO) estimates that nearly half of all vaccines worldwide are wasted before reaching patients. Although vaccine losses occur for several reasons, including transportation damage, expired doses and unused vaccines from multi-dose vials, failures in the cold chain remain one of the leading causes.
Researchers now believe that challenge could soon become far less significant.
Early-stage clinical studies have shown promising results for a newly stabilised vaccine formulation that remains effective without relying on continuous refrigeration. According to Prof. Saul Faust, Director of the NIHR Clinical Research Facility in Southampton, the vaccine generated immune responses comparable to those of the conventional refrigerated version while proving to be safe and well tolerated during initial trials.
“This obviously has potential to remove cold chain dependence, reduce wastage and improve access,” Faust said.
The research team is preparing to launch a larger clinical trial involving 160 participants in the coming months. Because the original vaccine has already been approved and licensed, the upcoming study is expected to serve as the final stage of evaluation, eliminating the need for the extensive large-scale trials typically required for entirely new vaccines.
The project aligns with the World Health Organization’s goal of developing vaccines capable of remaining stable at temperatures of up to 30 degrees Celsius and 75 per cent relative humidity, making them more suitable for use in challenging environments.
Scientists achieved the breakthrough by using trehalose, a naturally occurring sugar known for its ability to protect biological materials from heat damage. The technique could potentially be applied to many existing vaccines, although researchers note that current mRNA vaccines cannot yet be stabilised using the same method.
Beyond vaccines, the technology may also benefit temperature-sensitive medicines such as monoclonal antibodies, which currently require refrigerated storage throughout the supply chain.
Researchers say separate laboratory data indicate that the vaccine’s components can also withstand repeated temperature fluctuations ranging from -20°C to +40°C without losing stability. This resilience could allow vaccines to remain effective after being transported in freezing aircraft cargo holds before later being exposed to high temperatures during road transportation.
If subsequent trials confirm the early findings, the innovation could significantly reduce vaccine wastage, lower distribution costs and expand immunisation coverage, particularly in underserved communities where maintaining refrigeration has long been a major logistical challenge.
Health experts believe the development represents an important step toward improving global vaccine access by making immunisation programmes more resilient, efficient and capable of reaching populations that have historically been difficult to serve.
